Novel Topical Treatment for Postherpetic Neuralgia

带状疱疹后神经痛的新型局部治疗

• 批准号: 6991051
• 负责人: Charles J Gauntt
• 金额: $ 19.69万
• 依托单位: BIOMEDICAL DEVELOPMENT CORPORATION
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6991051
• 关键词: analgesia; chemotherapy; chronic pain; clinical research; clinical trials; drug delivery systems; drug design /synthesis /production; drug screening /evaluation; human subject; human therapy evaluation; local anesthetics; patient oriented research; polymers; shingles; slow release drug; topical drug application

DESCRIPTION (provided by applicant): The goal of this project is to develop a novel topical drug delivery vehicle to treat postherpetic neuralgia [PHN). PHN is defined as pain in the affected dermatome that persists or appears after the rash of herpes zoster (HZ) has healed. Although many cases of PHN resolve over time, for many patients the pain is chronic, causing a devastating impact on quality of life. Systemic treatments for PHN are associated with undesirable adverse effects, which can be particularly problematic for elderly patients. Topical treatments such as capsaicin cream, acetylsalicylic acid (aspirin), anesthetic creams, and lidocaine patches either require multiple daily applications or are limited in their use due to the potential for elevated systemic absorption of the topical compound. In previous work, Biomedical Development Corporation (BDC) has developed a novel polymer-based coating composition that is useful for several biomedical applications. The coating is capable of sustained topical drug delivery. The objective of this project is to use these coatings as a treatment for the pain associated with postherpetic neuralgia. The Specific Aims of the grant are as follows: Specific Aim 1: Formulate Coatings for the Treatment of Postherpetic Neuralgia Specific Aim 2: Demonstrate Efficacy of Coatings in a Human Clinical Trial Relevance to Public Health: Herpes zoster (shingles) is one of the most common neurologic diseases in the U.S. Although there have been no systematic attempts to investigate the prevalence of post herpetic neuralgia, estimates have ranged from 500,000 to 1 million in the U.S. The incidence of PHN among those with herpes zoster ranges from 10 to 70 percent and increases with advancing age and the intractability of the pain may also increase with age. The incidence of herpes zoster, and therefore the incidence of PHN, is predicted to increase in the coming decades because of both the aging population and as a consequence of childhood varicella vaccination. The ongoing spontaneous pain and particularly the allodynic component of PHN can be debilitating and can lead to co-morbid conditions such as depression, social isolation, anxiety and sleep disturbance, as well as increased health care utilization.

描述（由申请人提供）：该项目的目标是开发一种新的局部药物递送载体来治疗带状疱疹后神经痛[PHN]。PHN被定义为在带状疱疹（HZ）皮疹愈合后持续或出现的受影响皮肤的疼痛。尽管许多PHN病例会随着时间的推移而消退，但对许多患者来说，疼痛是慢性的，对生活质量造成了毁灭性的影响。PHN的全身治疗与不良反应有关，这对老年患者尤其成问题。局部治疗，如辣椒素乳膏、乙酰水杨酸（阿司匹林）、麻醉剂和利多卡因贴剂，要么需要每天多次使用，要么由于局部化合物可能增加全身吸收而限制使用。